MX315565B - - Google Patents

Info

Publication number
MX315565B
MX315565B MX2010006690A MX2010006690A MX315565B MX 315565 B MX315565 B MX 315565B MX 2010006690 A MX2010006690 A MX 2010006690A MX 2010006690 A MX2010006690 A MX 2010006690A MX 315565 B MX315565 B MX 315565B
Authority
MX
Mexico
Application number
MX2010006690A
Other versions
MX2010006690A (es
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39111664&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX315565(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of MX2010006690A publication Critical patent/MX2010006690A/es
Publication of MX315565B publication Critical patent/MX315565B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
MX2010006690A 2007-12-17 2008-12-05 Prevencion de infecciones oportunistas en individuos inmuno-comprometidos. MX2010006690A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07123390A EP2072052A1 (en) 2007-12-17 2007-12-17 Prevention of opportunistic infections in immune-compromised subjects
PCT/EP2008/066850 WO2009077352A1 (en) 2007-12-17 2008-12-05 Prevention of opportunistic infections in immune-compromised subjects

Publications (2)

Publication Number Publication Date
MX2010006690A MX2010006690A (es) 2010-09-10
MX315565B true MX315565B (es) 2010-09-10

Family

ID=39111664

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006690A MX2010006690A (es) 2007-12-17 2008-12-05 Prevencion de infecciones oportunistas en individuos inmuno-comprometidos.

Country Status (18)

Country Link
US (2) US9217133B2 (es)
EP (2) EP2072052A1 (es)
CN (1) CN101909644A (es)
AU (1) AU2008337646B2 (es)
BR (1) BRPI0820837A2 (es)
CA (1) CA2709396A1 (es)
ES (1) ES2576642T3 (es)
IN (1) IN2010DE04311A (es)
MX (1) MX2010006690A (es)
MY (1) MY185938A (es)
PH (1) PH12010501367B1 (es)
PL (1) PL2234627T3 (es)
PT (1) PT2234627T (es)
RU (1) RU2486910C2 (es)
SG (1) SG186657A1 (es)
UA (1) UA102830C2 (es)
WO (1) WO2009077352A1 (es)
ZA (1) ZA201005088B (es)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101855554B (zh) 2007-09-07 2014-05-14 儿童医院医学中心 分泌者、Lewis和唾液酸化抗原水平作为疾病预测指标的用途
EP2072052A1 (en) 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
EP2451462B1 (en) 2009-07-06 2017-09-06 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
MY189329A (en) * 2009-07-15 2022-02-04 Nutricia Nv Mixture of non-digestible oligosaccharides for stimulating the immune system
WO2011008087A1 (en) * 2009-07-15 2011-01-20 N.V. Nutricia Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit
US9585920B2 (en) 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
US9408880B2 (en) 2013-12-20 2016-08-09 Katherine Rose Kovarik Method and system for prevention and treatment of allergic and inflammatory diseases
US9457077B2 (en) 2009-11-18 2016-10-04 Katherine Rose Kovarik Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
WO2011136637A1 (en) * 2010-04-27 2011-11-03 N.V. Nutricia Use of human milk oligosaccharides in infant nutrition
ES2490269T3 (es) * 2010-04-27 2014-09-03 N.V. Nutricia Uso de oligosacáridos de leche humana en la nutrición de bebés
CN103025749B (zh) 2010-06-01 2016-06-01 格礼卡姆股份公司 2’-o-岩藻糖基乳糖的多晶型物及其制备
EP2455387A1 (en) * 2010-11-23 2012-05-23 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
EP2465508A1 (en) * 2010-11-23 2012-06-20 Nestec S.A. Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases
EP2465509A1 (en) * 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharide composition for treating acute respiratory tract infections
MX355780B (es) * 2010-12-31 2018-04-30 Abbott Lab Fórmula pediátrica sintética para estimular células nerviosas entéricas en el tracto gastrointestinal.
EP3510873A1 (en) 2010-12-31 2019-07-17 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
MX352040B (es) 2010-12-31 2017-11-07 Abbott Lab Formulaciones nutricionales que incluyen los oligosacaridos de leche humana y los acidos grasos poliinsaturados de cadena larga y usos de las mismas.
CA2822497C (en) 2010-12-31 2020-07-28 Abbott Laboratories Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
CN110051676A (zh) 2010-12-31 2019-07-26 雅培制药有限公司 用于调节炎症的人乳寡糖
NZ611807A (en) 2010-12-31 2015-02-27 Abbott Lab Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
EP3473257A1 (en) * 2010-12-31 2019-04-24 Abbott Laboratories Methods of using human milk oligosaccharides for improving airway respiratory health
NZ612386A (en) * 2010-12-31 2015-02-27 Abbott Lab Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
US10583033B2 (en) 2011-02-04 2020-03-10 Katherine Rose Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US10085938B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for preventing sore throat in humans
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11191665B2 (en) 2011-02-04 2021-12-07 Joseph E. Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10010568B2 (en) 2011-02-04 2018-07-03 Katherine Rose Kovarik Method and system for reducing the likelihood of a spirochetes infection in a human being
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US10111913B2 (en) 2011-02-04 2018-10-30 Joseph E. Kovarik Method of reducing the likelihood of skin cancer in an individual human being
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
CN104126749A (zh) † 2011-02-10 2014-11-05 雀巢产品技术援助有限公司 使用人乳中发现的特定量的寡糖的组合调节双歧杆菌属的生长
US9567361B2 (en) * 2011-05-13 2017-02-14 Glycosyn LLC Use of purified 2′-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics
MX352677B (es) 2011-06-20 2017-12-04 Heinz Co Brands H J Llc Composiciones probioticas y metodos.
DK2734210T3 (en) * 2011-07-22 2018-01-22 Abbott Lab GALACTOOLIGOSACCHARIDES FOR THE PREVENTION OF DAMAGE TO AND / OR PROMOTION OF HEALING OF THE MAVE GAS CHANNEL
BR112014004772A2 (pt) 2011-08-29 2017-03-21 Abbott Lab oligossacarídeos do leite humano para evitar danos e/ou promover a cura do trato gastrointestinal
PL2768314T3 (pl) * 2011-10-18 2016-05-31 Nestec Sa Kompozycja do zastosowania do zwiększania wrażliwości na insulinę i/lub zmniejszania oporności na insulinę
WO2013057062A1 (en) * 2011-10-18 2013-04-25 Nestec S.A. Composition for use in the promotion of intestinal angiogenesis and of nutrient absorption and of enteral feeding tolerance and/or in the prevention and/or treatment of intestinal inflammation and/or in the recovery after intestinal injury and surgery
CN110201003A (zh) 2012-02-29 2019-09-06 伊西康内外科公司 微生物区系的组合物及与其相关的方法
MY168661A (en) * 2012-03-27 2018-11-28 Abbott Lab Methods for modulating cell-mediated immunity using human milk oligosaccharides
ES2572831T3 (es) * 2012-09-14 2016-06-02 Abbott Laboratories Composiciones nutricionales para su uso en métodos para modular los niveles de corticosterona en individuos con estrés psicológico
WO2014130789A1 (en) 2013-02-21 2014-08-28 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
US10165788B2 (en) * 2013-06-17 2019-01-01 The Regents Of The University Of California Methods and compositions for improved digestion of milk oligosaccharides
EP2815757A1 (en) * 2013-06-17 2014-12-24 Hestia Investments Composition for topical use in prevention and treatment of bacterial and fungal infections of skin and mucosa
WO2015071401A1 (en) 2013-11-15 2015-05-21 Nestec S.A. Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants or young children born by c-section
MX2016006221A (es) 2013-11-15 2016-08-08 Nestec Sa Composiciones para usar en la prevencion o tratamiento de la enterocolitis necrotizante en infantes y niños pequeños.
ES2857077T3 (es) * 2013-11-15 2021-09-28 Nestle Sa Composiciones para su uso en la prevención o tratamiento de infecciones del TRS en bebés o niños jóvenes en riesgo
WO2015077233A1 (en) 2013-11-19 2015-05-28 Abbott Laboratories Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
MX2016013064A (es) 2014-04-08 2017-01-26 Abbott Lab Metodos para mejorar las respuestas inmune innata y/o deteccion de patogenos de la mucosa mediante oligosacaridos de la leche humana.
CN107249611A (zh) * 2014-10-24 2017-10-13 进化生物系统股份有限公司 活化的双歧杆菌及其应用方法
GB2551642B (en) 2014-10-31 2020-09-23 Pendulum Therapeutics Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
MX2017006701A (es) * 2014-11-26 2018-02-13 Abbott Lab Fórmula infantil con rrr-alfa-tocoferol,2'-fucosilactosa y un probiótico.
US10987368B2 (en) 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
US10881674B2 (en) 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
US10835544B2 (en) 2014-12-08 2020-11-17 Glycom A/S Synthetic composition for regulating satiety
AU2016227596B2 (en) * 2015-03-05 2020-01-16 Société des Produits Nestlé S.A. Compositions for use in improving stool consistency or frequency in infants or young children
CN107405354A (zh) 2015-03-05 2017-11-28 格礼卡姆股份公司 治疗急性呼吸道感染的组合物和方法
WO2016139328A1 (en) 2015-03-05 2016-09-09 Nestec S.A. Compositions for use in the prevention or treatment of otitis or bronchitis in infants or young children
EP3264923B1 (en) 2015-03-05 2023-01-11 Société des Produits Nestlé S.A. Compositions for use in the prevention or treatment of gastrointestinal infections in infants or young children
US10857167B2 (en) 2015-04-28 2020-12-08 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain
CA3017357A1 (en) * 2016-03-11 2017-09-14 Evolve Biosystems, Inc. A transient commensal microorganism for improving gut health
WO2017215721A1 (en) * 2016-06-15 2017-12-21 Glycom A/S Synthetic compositions comprising human milk oligosaccharides for use γν the prevention and treatment of disorders
WO2019031961A1 (en) 2017-08-11 2019-02-14 N.V. Nutricia OLIGOSACCHARIDE OF HUMAN MILK TO IMPROVE PHYSICAL IMMUNE CONDITION
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
EP3583858A1 (en) * 2018-06-20 2019-12-25 DuPont Nutrition Biosciences ApS Compositions for treating or preventing gut barrier dysfunction
US11554131B2 (en) * 2018-05-31 2023-01-17 Glycom A/S Mixture of HMOs for treating autoimmune diseases
US20220241354A1 (en) * 2019-06-05 2022-08-04 Morinaga Milk Industry Co., Ltd. Composition
EP4061390A1 (en) * 2019-11-20 2022-09-28 Abbott Laboratories Nutritional compositions for treating a clostridium difficile infection
CN112870232A (zh) * 2019-11-29 2021-06-01 内蒙古伊利实业集团股份有限公司 乳双歧杆菌bl-99提升肠道细菌感染抗性和肠道免疫力的应用
CN118402616A (zh) * 2020-04-03 2024-07-30 内蒙古伊利实业集团股份有限公司 可提升生物体对金黄色葡萄球菌感染的抵御能力的母乳低聚糖
US20240000868A1 (en) * 2020-11-16 2024-01-04 Inner Mongolia Yili Industrial Group Co., Ltd. Composition Containing Bifidobacterium Lactis and Human Milk Oligosaccharides and Application Thereof
CN116195629A (zh) * 2021-11-30 2023-06-02 内蒙古伊利实业集团股份有限公司 婴儿双歧杆菌ylgb-1496在抗衰老、提高先天免疫方面的新应用
CN116195740A (zh) * 2021-11-30 2023-06-02 内蒙古伊利实业集团股份有限公司 可提升生物体对金黄色葡萄球菌感染抵御能力的益生元与益生菌组合物
WO2024013393A1 (en) * 2022-07-15 2024-01-18 Dsm Ip Assets B.V. Combination of bifidobacterium and fucosylated hmo for use in increasing nmn or nad+
TW202428293A (zh) * 2022-09-27 2024-07-16 瑞士商雀巢製品股份有限公司 長雙歧桿菌過渡微生物之用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839281A (en) 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
DE69223615T2 (de) 1992-07-06 1998-04-09 Nestle Sa Lactobacillus Acidophilus enthaltende Antigastritis-Mittel
DK0768375T4 (da) * 1992-07-06 2002-09-16 Nestle Sa Mælkesyrebakterier
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
US6045854A (en) * 1997-03-31 2000-04-04 Abbott Laboraties Nutritional formulations containing oligosaccharides
WO1999017788A1 (en) * 1997-10-06 1999-04-15 Abbott Laboratories Composition of treatment of candidiasis
US5902743A (en) * 1998-03-20 1999-05-11 Wisconsin Alumni Research Foundation Probiotic bifidobacterium strain
US20020019991A1 (en) * 1998-04-30 2002-02-14 Abbott Laboratories Compositions containing an alpha 1,2-fucose linkage and uses thereof
US6841149B1 (en) * 1998-05-29 2005-01-11 Agri-King, Inc. Probiotic mixture intended for monogastric animals to control intestinal flora populations
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
US7101565B2 (en) * 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
ES2416287T3 (es) * 2003-06-23 2013-07-31 Nestec S.A. Empleo de una fórmula nutritiva para la función óptima de la barrera intestinal
NZ546664A (en) * 2003-10-24 2009-04-30 Nutricia Nv Synbiotic composition for infants
CA2548140A1 (en) 2003-12-05 2005-06-23 University Of Massachusetts Oligosaccharide compositions and use thereof in the treatment of infection
US7137361B2 (en) 2004-06-22 2006-11-21 Federal-Mogul World Wide, Inc. Cylinder head gasket with one-way coolant flow valve
EP1714660A1 (en) 2005-04-21 2006-10-25 N.V. Nutricia Uronic acid and probiotics
EP1776877A1 (en) * 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
NZ571158A (en) * 2006-03-10 2011-08-26 Nutricia Nv Use of non-digestible saccharides administered to a pregnant woman for giving an infant the best start after birth
EP2117355B1 (en) 2007-03-13 2017-04-26 N.V. Nutricia Method of improving skills with a composition comprising non-digestible saccharide
US8197872B2 (en) * 2007-05-17 2012-06-12 The Regents Of The University Of California Human milk oligosaccharides to promote growth of beneficial gut bacteria
EP2072052A1 (en) 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
ES2395838T3 (es) * 2007-12-21 2013-02-15 Compagnie Gervais Danone Método para disminuir el contorno abdominal administrando una bacteria del tipo Bifidobacterium

Also Published As

Publication number Publication date
EP2072052A1 (en) 2009-06-24
MX2010006690A (es) 2010-09-10
PH12010501367B1 (en) 2009-06-25
BRPI0820837A2 (pt) 2015-06-16
CN101909644A (zh) 2010-12-08
CA2709396A1 (en) 2009-06-25
EP2234627A1 (en) 2010-10-06
WO2009077352A1 (en) 2009-06-25
AU2008337646A1 (en) 2009-06-25
PL2234627T3 (pl) 2016-12-30
SG186657A1 (en) 2013-01-30
PT2234627T (pt) 2016-07-26
US9217133B2 (en) 2015-12-22
AU2008337646B2 (en) 2014-07-17
US20120308527A1 (en) 2012-12-06
ES2576642T3 (es) 2016-07-08
EP2234627B1 (en) 2016-05-25
IN2010DE04311A (es) 2010-11-12
MY185938A (en) 2021-06-14
ZA201005088B (en) 2017-03-27
RU2010129685A (ru) 2012-01-27
UA102830C2 (ru) 2013-08-27
US20100260720A1 (en) 2010-10-14
RU2486910C2 (ru) 2013-07-10

Similar Documents

Publication Publication Date Title
IN2010DE04311A (es)
CN300728665S (zh) 刀盒(118)
CN300729931S (zh) 充电器转换器(sln)
CN300853345S (zh) 水龙头(11)
CN300829417S (zh) 面包架(sk27)
CN300815142S (zh) 包装箱(四)
CN300728483S (zh) 甩脂机
CN300811163S (zh) 面料(96)
CN300797750S (zh) 榨菜包装袋(榨菜丝1)
CN300726097S (zh) 伞(1)
CN300728437S (zh) 射灯(led-f)
CN300729318S (zh) 窗帘装饰杆(二)
CN300728119S (zh) 头框(t09109)
CN300726211S (zh) 布(47)
CN300791668S (zh) 门板(by-07-2007)
CN300726585S (zh) 竹凉席(老板型-4)
CN300759018S (zh) 包装袋(22)
CN300726257S (zh) 墙纸(11)
CN300731891S (zh) 窗帘杆装饰头(2296)
CN300731612S (zh) 台球桌腿
CN300726267S (zh) 墙纸(26)
CN300726575S (zh) 枕套(似水流年)
CN300728390S (zh) 节能灯管
CN300777288S (zh) 镶嵌玻璃(230)
CN300866214S (zh) 装饰织物(6)

Legal Events

Date Code Title Description
FG Grant or registration